Navidea, FDA settle on details for NAV5001 trials

08/22/2013 | AuntMinnie.com (free registration)

Navidea Biopharmaceuticals has reached an agreement with the FDA regarding special-protocol assessments for Phase III trials for Navidea's investigational imaging agent NAV5001. The agent targets the brain's dopamine transporters for distinguishing Parkinsonian syndromes with SPECT imaging. Navidea plans to begin the trials this year.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Medical Director - Physician
Willamette Valley Community Health
Salem, OR